Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

Background: A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mesía, R., Rivera, F., Kawecki, A., Rottey, S., Hitt, R., Kienzer, H., Cupissol, D., De Raucourt, D., Benasso, M., Koralewski, P., Delord, J.-P., Bokemeyer, C., Curran, D., Gross, A., Vermorken, J. B.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2010
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2946862/
https://ncbi.nlm.nih.gov/pubmed/20335368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdq077
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados